40112-93-4

Usage

Uses

Used in Pharmaceutical Industry:
4-MethoxycarbonylMethylene-piperidine-1-carboxylic acid benzyl ester is used as an antidepressant medication for the treatment of depression and social anxiety disorder. It works by inhibiting the breakdown of neurotransmitters in the brain, leading to an improvement in mood and a reduction in feelings of anxiety.
Used in Mental Health Treatment:
4-MethoxycarbonylMethylene-piperidine-1-carboxylic acid benzyl ester is used as a therapeutic agent for individuals suffering from depression and social anxiety disorder. Its ability to block the breakdown of neurotransmitters helps to alleviate symptoms and improve the overall quality of life for patients.
Used in Research and Development:
4-MethoxycarbonylMethylene-piperidine-1-carboxylic acid benzyl ester is utilized in research and development for the study of monoamine oxidase A (MAO-A) inhibitors and their potential applications in the treatment of various mental health disorders. Its reversible inhibition of MAO-A makes it a valuable compound for understanding the mechanisms of action and side effects associated with this class of drugs.
Used in Drug Formulation:
4-MethoxycarbonylMethylene-piperidine-1-carboxylic acid benzyl ester is used in the formulation of pharmaceutical products, specifically as an active ingredient in antidepressant and anti-anxiety medications. Its favorable side effect profile and effectiveness in treating mood disorders make it a preferred choice for drug development in the mental health sector.

Upstream product

• 19099-93-5 benzyl 4-oxo-1-piperidinecarboxylate 
• 21204-67-1 methyl (triphenylphosphoranylidene)acetate 

Downstream Products

• 1419221-95-6 6-benzyl 1-methyl 6-azaspiro[2.5]octane-1,6-dicarboxylate 
• 30338-85-3 benzyl 4-(2-methoxy-2-oxoethylidene)-3,6-dihydiropyridine-1(2H)-carboxylate 

Relevant academic research and scientific papers

4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors

The present invention provides 6-5 membered fused pyridine ring compounds according to Formula I or pharmaceutically acceptable salts thereof. or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of 6-5 membered fused pyridine ring compounds in the treatment of Bruton's Tyrosine Kinase (Btk) mediated disorders.

N-PIPERIDIN-4-YL DERIVATIVES

The invention relates to a N-piperidin-4-yl derivative having the general Formula I or a pharmaceutically acceptable salt thereof, to pharmaceutical compositions comprising the same and to the use of said N-piperidin-4-yl derivatives for the treatment and prevention of endometriosis, for the treatment and prevention of pre-menopausal and peri-menopausal hormone-dependent breast cancer, for contraception, or for the treatment of uterine fibroids or other menstrual-related disorders.

Optimization of azepanone calcitonin gene-related peptide (CGRP) receptor antagonists: Development of novel spiropiperidines

Several novel spiropiperidine-based CGRP receptor antagonists have been developed that maintain good potency and have reduced potential for metabolism.

HETEROCYCLIC BENZODIAZEPINE CGRP RECEPTOR ANTAGONISTS

Compounds of formula I: (where variables R2, R7, D, W, X, Y and Z are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

CGRP RECEPTOR ANTAGONISTS

The present invention is directed to compounds of Formula I: Formula I: I and Formula II: (where variables R1, R2, R3, R4, A, B, J, Q, T, V, W, X and Y are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

CGRP RECEPTOR ANTAGONISTS

Compounds of Formula (I): and Formula (II): (where variables R2, R4, A, B, D, W, X, Y and Z are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

CGRP RECEPTOR ANTAGONISTS

Compounds of Formula (I), (where variables R1, A, B, W, X, Y and Z are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.